What is NK-cell therapy?
Trillions of cells replicate in a person every day. Under the influence of carcinogens (smoking, ionizing radiation, Helicobacter pylori, etc.), about 500,000 to 1 million cells can mutate during the replication process every day. Some mutant cells further become cancer cells.
Plasmodium legione
After thousands of years of evolution, the human body has formed a sophisticated defense system, established a powerful immune corps, and stocked a large number of elite soldiers, always protecting us and keeping us away from cancer. Among them, the bone marrow is the headquarters of the immune system. Here, hematopoietic stem cells differentiate into immune fighters with different functions. They have their own army territory and job responsibilities.
Sunt tres main exercituum:
Caput 1. Legio: Linfocito
Thymus vulgaris-T lymphocytes dependens lymphocytes, pelagus lymphocytes, in sanguine quod recirculation
B lymphocytes, in bursa bursa vel develop eius membra isoactive (medulla) quae possunt esse propriae differentiae in antibody-plasma producendo cum cellulis per antigen, quod moveatur
NK cellulis, gene LAK cellulis non necesse est effectum occisio sensitisation
2. auxiliaris Legio: Expositio Antigen
, Mononuclear macrophage phagocytosis, nunc TD antigen, initientur per immune responsio, anti-tumore effectus, media secretio bioactive
DC cellulis per antigen visum munus coetus ex heterogeneis cellas fortissimum, et prosternerem preces sunt modo professional gene-T cellulis constans, cellulis potest eu innocentium
3. Alius immunes legionibus cellulam
Neutrophils, eosinophilic / basic Granulocytes et malum cellulis, platelets, rufus sanguine cellulis.
Pendicularis NK Cell Quod est?
Nullam immune bellum: Primum est lignum, NK, Cell
Corporis immune prorsus idem certamen hostibus arma deduci anti- elit. Nullam ut generi serenus partitio indiget tribus exercitibus proelio scrupulosam consilio rebus ordinatis unum cecidit incubuere hostis deleri.
In proelio contra cancer cellulis, natural killer (NK) cells bear the brunt. It is the first to directly kill cancer cells when they reach the tuberculum micro environment while secreting secret weapon chemokines to recruit dendritic cells (CD103 + DC). Then, activated dendritic cells carry tumor antigens to the lymph nodes, presenting the characteristics of cancer cells to killer T cells. T cells then rush to the battlefield to kill cancer cells together with NK cells.
Pendicularis NK Cell fortissimum est effectus occisio
NK cellulis
Full nomen Naturalis Cell Artist: Orff
Fons, Orta directe a os medulla, ex in progressionem Microambiente quod positum est in medullae ossium
Munus: Cellae scopum ab NK interfectae praecipue sunt cellae tumores, cellae virus infectae, pathogens maiores (ut fungi et parasiti), organa et tela allotransplantata.
Plenum nomen cellarum NK est Cell interfectoris Naturalis (NK), quae est tertia caterva lymphocytarum in parallelis cum T et B cellulis in core cellulis legionis. NK cellae magnae sunt et particulas cytoplasmicos continent, unde lymphocytae magna-particulae dicuntur. Habet tres notas maximas:
Primo corporis innata feugiat. Is est certus in prima acie miles. Primo impetu erit NK cellulis tumor pene cellula.
Alio modo, quia habet effectum antitumor lato spectro, non requirere specifica recognition tumore, et non concluditur major in universa Producto (MHC) machinationem inhibendi ius cell operatio per superficiem. Satus est ieiunas et T cellulis oportet distinguere munera ante antigenos "Hostis et inimicus".
Tertio, de statu est, opportune feedback. Semel in "statu hostes" enim inveni, ut celeriter "retulit," et immune defensionem et immune occisio munera totius systematis immunis es activated.
Unde ad occidere cancer effectus est, omnipotens.
Autem, ad numerum NK cellulis humana corpus est relative parva, rationem XV% de numerus totalis de lymphocytes in periphericis sanguinem, et fere III% ad IV% in splenem confert et reponit. Possunt etiam in pulmonem, iecur intestinorum mucosa sed thymi, nodorum catheter rarum et pectore.
Quam NK cellulis occidere cancer cellulis?
NK cellulis, in prima linea defensionis ludunt est key partes in cancer. NK cellulis, cancer effectus anti habere tria:
One is the direct killing of tumor cells, killing tumor cells by releasing perforin and granzyme or death receptors; the second is that it acts as a regulatory cell of the immune system by activating cytokines and chemokines, activating T cells, etc. The lethal effect.
The third is the formation of ADCC (antibody-dependent cell-mediated cytotoxicity). When B cells find cancer cells, they will quietly leave specific IgG antibodies on the cancer cells as a mark to remind NK cells to see this mark. NK cells see each other and kill them. With the help of macrophages and B cells, the morale of cancer-killing increased greatly.
NK cellulis nihilum redigat cancer cellulis
NK cellulis humana in sanguine est et esse "Primus responders". Est sicut quis tristis est officium fuit in corpore. Sicut sanguis circum, NK cellulis permanere contact cum aliis cellulis patrolling. Cellulae deprauationem aliquando invenitur corpus continuo firma apeirian temporibus insidiantes impie agere. Et partes continet impetum et dimittere Cytotoxic perforin granzyme et scopum in cellula membrana ante T cellulis instructa triggering in exitium sui-cancer cellulis. Et caule cellulis quoque eliminate cancer metastasis ne grassentur in corpus et auxilium.
Pendicularis NK cellula-fundatur immunotherapy
Isque cum impetu statim se defendere ergastula NK cellulis pauca immune ratio rationem albi sanguinem cellulis solum X%. Et factum est ut post XXV annos aetatis studiis inveni, quod decrescat et numerum NK cellulis humana immunitatem, crescere me autem minui. Numerum NK cellulis tumor agentis ad patiens et patiens quodammodo mutari eximitur tumor et potest non exerere anticancer effectus.
Inquisitores nunc positus in «adoptionis« pendicularis NK cellula-Lorem colligendis NK cellulis, ex intimis nexibus divinciuntur offerentium voluntatibus et injicerent in aegris. Hoc probatur esse tutum est, et cellula dissimilis T Lorem, NK cellulis, ne faciam versus inserere in recipiens, hospes morbum texturis.
Praesens internationalis NK cellula consilia tumoris immunotherapy sunt:
1. In vitro activated autologous or allogeneic NK cell therapy;
2. Combine NK cells and monoclonal antibodies (such as immune checkpoint inhibitors) to induce antibody-specific cytotoxicity;
3. Construct NK, itemque car-cell immunotherapy.
Auto receptoribus Activate pendicularis NK cellulis, cellam membranis Clausus machinationem inhibendi ius receptores pendicularis NK ibi elementorum est vel activa stimulate
pendicularis NK cell operatio lysis ad augendam receptores, metu perculsa receptis
LAPIS inhibitors tandem coniunctim afficient vniuersa sunt immunes: LAPIS Lorem combined per pendicularis NK altera target-posse duci immunotherapy multa genera tumores, qui non obediunt currently existentium therapies.
NK cells modified by chimeric antigen receptor: can significantly improve the specificity of NK cell efficacy. This idea is similar to the construction of CAR-T: CAR includes extracellular recognition domains (such as scFv) to recognize tumor-specific antigens; a transmembrane domain, and an intracellular signaling domain (CD3ζ chain) can induce NK cells activation.
Quae est differentia inter pendicularis NK cellulis et T cellulis Lorem?
Immunotherapy cancer in agro: homines enim est focusing movens ad tumor anti-T cellulis. Currently, FDA probatus car duo T-cell therapies.
T cellulis et cancer cellulis occidere NK cellulis cognoscitur nisi procedant adfecit.
T cellulis opus "nunc" target cellulis quibusdam aliis immunis cellulis suis, ut eos in proelium alienum cellulis et T cellulis aggregatum exempla.
NK cells recognize the pattern of cancer cell changes and are the first line of defense of the immune system. Unlike T cells, they directly detect and destroy infected and malignant cells without having to be activated or “trained” to respond to cancer cells. However, it is now well known that exposure to cytokines, which are components of the immune system, activates NK cells more effectively.
Naturalis interfectorem cellulis monstrantur viridi impetus ani mus. NK cellulis et cancer potest esse clavem immunotherapy. Hyacinthum ostendit venis. Fons Image: Dr. Michaelis Ardolino et Brian weist Dr.
Lorem cellula commoda NK,
1. Therapia cellula immunis est quarta methodus curationis post chirurgicam, chemotherapyam et radiotherapiam. NK cellula therapia cum radiotherapia et chemotherapy coniuncta efficaciter removere potest cellulas tumores, quae manu funditus tolli non possunt;
2. NE una cum cellula radiochemotherapy Lorem potest emendare efficacia radiochemotherapy ex parte minuere, et effectus;
3. For advanced cancer patients who are not suitable for surgery, radiotherapy, or chemotherapy, NK cell therapy is a better choice;
4. Ordinarius post surgery treatment ad NK cellulis potest ne cancer metastasis de coetus atque;
5. habet sublevantem cancer dolore, emendare somnum, patientes estote amplio qualitatem vitae cycle, et extend patientes estote vitam;
6. Pro populo sano, usus NK cellae therapiae periculum cancri minuere potest.
Pendicularis NK Cell Therapy Internationalis Update
Iaponica pendicularis NK cellula immunotherapy
In order to improve the activity and number of NK cells in the body, Japanese scientists have invented a multiplier method, which is to extract 50ml from human blood, isolate a small amount of NK cells and then expand the culture to increase the number to the original 1000 times, the number reaches 1 billion to 5 billion and is then returned to the body, a large number of NK cells will circulate 3000 to 4000 times with the blood system, killing cancer cells, aging cells, diseased cells, bacteria and viruses in the body Once again, to achieve the purpose of anti-cancer, improve immunity and prolong survival.
American pendicularis NK cellula immunotherapy
Civitatibus Foederatis Americae NK cellulis includitur in iudiciis immunotherapy cancer!
Mulier cum myeloid leukemia anguli (AML) is dying after repeated chemotherapy failures. As a final attempt, she received an experimental cell infusion of natural killer (NK) cells donated by her son. After 4 days, the osmotic skin lesions disappeared, and soon she entered a state of relief.
Although NK cell therapy is still only in early clinical trials in the United States, clinical research is increasing.
A clinical trial led by Washington University in St. Louis showed that approximately 12 patients with AML and myelodysplastic syndrome (MDS) received NK cells. Half of the patients entered the remission period.
At present, MD Anderson at Dana Faber Cancer Institute is conducting a clinical trial, which will test the efficacy of NK cell therapy in patients with hematological tumors that relapse after stem cell transplantation. Patients who want to know the details can call + 91 96 1588 1588.
Quis Lorem cell idonea est ad NK, itemque?
1. ad aegros corpore tumorem pauperes manu tardus recuperare post surgery occulto metu ne revelli amet turpis.
2. After radiotherapy and chemotherapy, the immune system is low, the side effects are obvious (such as loss of appetite, nausea, hair loss, skin inflammation, etc.), and patients expect to increase the effect of chemoradiation.
3. aegroti, qui volunt ad consequi variis medicinales effectus ob timorem treatments ad latus effectus chemotherapy et Rectum.
4. aegroti provectus est ut propagationem cancer cellulis in corpus omne diduci sed conventional curatio modi fuerunt tua, et aegris qui exspectare longum protraham, et salvos amplio qualitatem vitae.
Lorem processus of curatio in cellula NK,
1. Blood collection: Extract 30–50 ml of peripheral blood of cancer patients and extract mononuclear cells;
2. Laboratory culture: In the laboratory, conduct NK cell induction and expansion for a period of 5-7 days;
3. Return: After the NK cell culture is completed, it is returned to the cancer patient like an infusion.
Lorem casu treatment of cell NK,
Case Source: An authoritative NK cell therapy clinic in Japan
Ms. Zheng, 50, was diagnosed with advanced pancreaticum cancer, (pancreatic tail), transferred to the liver, lungs, and pleura, and was diagnosed with cancerous peritonitis (chest wall, multiple nodules in the lungs). . After one cycle of Gemcitabine Gatige, the effect was not satisfactory, CA19-9 rose from 257,531 to 318,417. On the advice of the doctor, the whole genome was sequenced, and the result did not have any meaningful mutations. The doctor said that she had three months to six months at most. According to expert recommendations, Ms. Zheng began to reinject highly activated NK cells at a frequency of once every two weeks.
Immediately after finishing the first return, Ms. Zheng’s most obvious feeling was that she felt full of energy. She was always weak, and the pain symptoms were alleviated. With appetite, you can eat some light food.
Improviso, eius curatio est valde lenis. Post primum treatment, 19 CA9-7355 est directe ad NK, itemque activated post quartus highly curatio cellulam: et cecidit ad CXLI.
At the end of 2016, the rechecked CT images showed that metastatic lesions such as liver and lung bronchial lymph nodes had disappeared. Pancreatic cancer at the primary site has also shrunk by more than half.
Licet ea non plene recepit, curatio processus est valde teres. Ante incipiens curatio, factus est pessimus praeparata sunt, et curatione non posset perseverare, sed in fine primi curatione et corporalis conditio est vehementer patientes in melius.
